2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Eukaryotic Initiation Factor (eIF)

Eukaryotic Initiation Factor (eIF)

Eukaryotic Initiation Factor (eIF)

Related Products

PDF 0.58 MB

Eukaryotic initiation factors (eIFs) are proteins involved in the initiation phase of eukaryotic translation. These proteins help stabilize the formation of the functional ribosome around the start codon and also provide regulatory mechanisms in translation initiation.

Eukaryotic initiation factor 2B (eIF2B) is a guanine nucleotide-exchange factor which mediates the exchange of GDP (bound to initiation factor eIF2) for GTP, thus regenerating the active [eIF2.GTP] complex that is required for peptide-chain initiation. The activity of eIF2B is a key control point for eukaryotic protein synthesis and is altered in response to viral infection, hormones, nutrients, growth factors and certain stresses.

Eukaryotic translation initiation factor 4E (eIF4E) is best known for its function in the initiation of protein synthesis on capped mRNAs in the cytoplasm. Eukaryotic initiation factor (elF) 4A functions as a subunit of the initiation factor complex elF4F, which mediates the binding of mRNA to the ribosome.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-146805
    EB1
    		Inhibitor 99.91%
    EB1 is the inhibitor of kinases MNK with IC50s of 0.69 μM (MNK1) and 9.4 μM (MNK2). EB1 selectively inhibits the growth of cancer cells, but not normal cells. EB1 also increases cell apoptosis and suppresses eIF4E phosphorylation.
    EB1
  • HY-148450
    eIF4A3-IN-16
    		Inhibitor 98.37%
    eIF4A3-IN-16 (compound 60) is a silvestrol (HY-13251) analogue. eIF4A3-IN-16 interferes the assembling of eIF4F translation complex with EC50s of 1, 30 and 1 nM for myc-LUC, tub-LUC and the growth inhibition for MBA-MB-231 cells. eIF4A3-IN-16 can be used for the research of human cancer pathogenesis.
    eIF4A3-IN-16
  • HY-148446
    eIF4A3-IN-12
    		Inhibitor 99.70%
    eIF4A3-IN-12 (compound 62) is a silvestrol (HY-13251) analogue. eIF4A3-IN-12 interferes the assembling of eIF4F translation complex with EC50s of 4, 70 and 5 nM for myc-LUC, tub-LUC and the growth inhibition for MBA-MB-231 cells. eIF4A3-IN-12 can be used for the research of human cancer pathogenesis.
    eIF4A3-IN-12
  • HY-145309
    eIF4E-IN-3
    		Inhibitor
    eIF4E-IN-3 is a potent inhibitor of eukaryotic initiation factor 4e (eIF4e). eIF4E-IN-3 has the potential for researching eIF4e dependent diseases, including the research of cancer (extracted from patent WO2021003157A1, compound 485).
    eIF4E-IN-3
  • HY-148449
    eIF4A3-IN-15
    		Inhibitor
    eIF4A3-IN-15 (compound 52) is a silvestrol (HY-13251) analogue. eIF4A3-IN-15 interferes the assembling of eIF4F translation complex with EC50s of 11, 700 and 120 nM for myc-LUC, tub-LUC and the growth inhibition for MBA-MB-231 cells. eIF4A3-IN-15 can be used for the research of human cancer pathogenesis.
    eIF4A3-IN-15
  • HY-148443
    eIF4A3-IN-9
    		Inhibitor 99.71%
    eIF4A3-IN-9 (compound 57) is a silvestrol (HY-13251) analogue. eIF4A3-IN-9 interferes the assembling of eIF4F translation complex with EC50s of 29, 450 and 80 nM for myc-LUC, tub-LUC and the growth inhibition for MBA-MB-231 cells. eIF4A3-IN-9 can be used for the research of human cancer pathogenesis.
    eIF4A3-IN-9
  • HY-139872
    eIF4A3-IN-4
    		Inhibitor
    eIF4A3-IN-4 is a novel eIF4A inhibitor with an IC50 value of 8.6 μM.
    eIF4A3-IN-4
  • HY-148444
    eIF4A3-IN-10
    		Inhibitor
    eIF4A3-IN-10 (compound 58) is a silvestrol (HY-13251) analogue. eIF4A3-IN-10 interferes the assembling of eIF4F translation complex with EC50s of 35 and 100 nM for myc-LUC and the growth inhibition for MBA-MB-231 cells. eIF4A3-IN-10 can be used for the research of human cancer pathogenesis.
    eIF4A3-IN-10
  • HY-148452
    eIF4A3-IN-18
    		Inhibitor 99.58%
    eIF4A3-IN-18 (compound 74) is a silvestrol (HY-13251) analogue. eIF4A3-IN-18 interferes the assembling of eIF4F translation complex with EC50 values of 0.8, 35 and 2 nM for myc-LUC, tub-LUC and the growth inhibition for MBA-MB-231 cells. eIF4A3-IN-18 also has cytotoxicity to RMPI-8226 cells with an LC50 of 0.06 nM. eIF4A3-IN-18 can be used for the research of human cancer pathogenesis.
    eIF4A3-IN-18
  • HY-148451
    eIF4A3-IN-17
    		Inhibitor 99.56%
    eIF4A3-IN-17 (compound 61) is a silvestrol (HY-13251) analogue. eIF4A3-IN-17 interferes the assembling of eIF4F translation complex with EC50s of 0.9, 15 and 1.8 nM for myc-LUC, tub-LUC and the growth inhibition for MBA-MB-231 cells. eIF4A3-IN-17 can be used for the research of human cancer pathogenesis.
    eIF4A3-IN-17
  • HY-148447
    eIF4A3-IN-13
    		Inhibitor 99.92%
    eIF4A3-IN-13 (compound 75) is a silvestrol (HY-13251) analogue. eIF4A3-IN-13 interferes the assembling of eIF4F translation complex with EC50s of 0.6, 15 and 0.4 nM for myc-LUC, tub-LUC and the growth inhibition for MBA-MB-231 cells. eIF4A3-IN-13 can be used for the research of human cancer pathogenesis.
    eIF4A3-IN-13
  • HY-153399A
    ABBV-CLS-7262
    		Activator 98.03%
    ABBV-CLS-7262 is modulates the integrated stress response (ISR) for inhibition of ISR-related diseases.
    ABBV-CLS-7262
  • HY-148445
    eIF4A3-IN-11
    		Inhibitor 99.24%
    eIF4A3-IN-11 (compound 56) is a silvestrol (HY-13251) analogue. eIF4A3-IN-11 interferes the assembling of eIF4F translation complex with EC50s of 0.2, 4 and 0.3 nM for myc-LUC, tub-LUC and the growth inhibition for MBA-MB-231 cells. eIF4A3-IN-11 can be used for the research of human cancer pathogenesis.
    eIF4A3-IN-11
  • HY-148448
    eIF4A3-IN-14
    		Inhibitor 99.81%
    eIF4A3-IN-14 (compound 51) is a silvestrol (HY-13251) analogue. eIF4A3-IN-14 interferes the assembling of eIF4F translation complex with EC50s of 40 and 50 nM for myc-LUC and the growth inhibition for MBA-MB-231 cells. eIF4A3-IN-14 can be used for the research of human cancer pathogenesis.
    eIF4A3-IN-14
  • HY-129767
    CMLD012612
    		Inhibitor 99.52%
    CMLD012612 is an amidino-rocaglate containing a hydroxamate group and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012612 inhibits cell translation and is cytotoxic to NIH/3T3 cells with an IC50 value of 2 nM. CMLD012612 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A) and possesses potent anti-neoplastic activity.
    CMLD012612
  • HY-114568
    AMC-01
    		Modulator 99.38%
    AMC-01 is a potent chemical probe that regulates eIF2-α activity. AMC-01 induces protein kinase RNA activation (PKR) kinase and nuclear factor κb (NF-κB). AMC-01 inhibits apoptosis.
    AMC-01
  • HY-129769
    CMLD012073
    		Inhibitor
    CMLD012073 is an amidino-rocaglates and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012073 inhibits the growth of NIH/3T3 cells with an IC50 of 10 nM. CMLD012073 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A).
    CMLD012073
  • HY-129768
    CMLD012072
    		Inhibitor
    CMLD012072 is an amidino-rocaglates and is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. CMLD012072 can induce RNA clamping of eIF4A1 and eIF4A2 and possess potent anti-neoplastic activity.
    CMLD012072
  • HY-145361
    eIF4A3-IN-7
    		Inhibitor
    eIF4A3-IN-7 is a potent inhibitor of eIF4A3. eIF4A3-IN-7 has the potential for researching cancer and other dysproliferative diseases (extracted from patent WO2019161345A1, Compound 8).
    eIF4A3-IN-7
  • HY-134361
    ATP-γ-S tetrasodium
    		Chemical
    ATP-γ-S (tetrasodium) is a P2Y11 receptor agonist, an antioxidant and a neuroprotective agent. ATP-γ-S (tetrasodium) can be used as a substrate for the nucleotide hydrolysis and RNA unwinding activities of eukaryotic translation initiation factor eIF4A. ATP-γ-S (tetrasodium) is active in ATP hydrolysis.
    ATP-γ-S tetrasodium
Cat. No. Product Name / Synonyms Application Reactivity